Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Disposal of Biohazardous Cell Culture Waste – V 2.0

Posted on By


Biosimilars: SOP for Disposal of Biohazardous Cell Culture Waste – V 2.0


Standard Operating Procedure for Disposal of Biohazardous Cell Culture Waste in Biosimilar Labs

Department Biosimilars
SOP No. SOP/BS/048/2025
Supersedes SOP/BS/048/2022
Page No. Page 1 of 10
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the standardized procedure for the safe handling, segregation, treatment, and disposal of biohazardous waste generated during biosimilar cell culture operations in compliance with applicable biosafety and biomedical waste regulations.

2. Scope

This SOP applies to all personnel involved in the generation and handling of biohazardous waste including used cell culture materials, contaminated disposables, PPE, and biological fluids in biosimilar R&D laboratories.

3. Responsibilities

  • Lab Technicians: Segregate and label biohazard waste at point of generation and ensure timely disposal.
  • Housekeeping Personnel: Transport biohazard waste to designated collection points following protocol.
  • QA Department: Verify compliance through audit and maintain disposal documentation.
See also  Biosimilars: SOP for mRNA Transcript Analysis (RT-PCR) - V 2.0

4. Accountability

The Biosafety Officer is accountable for ensuring that biohazardous waste is disposed of as per Biomedical Waste Management Rules, 2016, and institutional biosafety guidelines.

5. Procedure

5.1 Classification of Biohazardous Waste

  1. Biohazard waste in biosimilar labs includes:
    • Used cell culture flasks, plates, and tubes
    • Contaminated pipettes, tips, gloves, gowns, and masks
    • Biological fluids and spent media
    • Sharps (e.g., syringes, broken glass)

5.2 Segregation and Labeling

  1. Use color-coded containers as per Biomedical Waste Rules:
    • Yellow bag: Infectious solids, PPE
    • Red bag: Contaminated plastic disposables
    • Blue container: Glassware
    • White container: Sharps
  2. Affix biohazard symbol and waste identification labels.

5.3 Decontamination Before Disposal

  1. Liquid waste (e.g., media, wash buffers) must be decontaminated by:
    • Autoclaving at 121°C for 30 min
    • Disinfection with 1% sodium hypochlorite (contact time: 30 min)
  2. Solid waste to be autoclaved before transfer to disposal area.
See also  Biosimilars: SOP for Agarose Gel Electrophoresis - V 2.0

5.4 Waste Collection and Transport

  1. Housekeeping staff to collect sealed bags/containers twice daily.
  2. Transport using dedicated, labeled trolleys to central biohazard storage area.
  3. Do not store unautoclaved infectious waste for more than 24 hours.

5.5 Final Disposal

  1. Coordinate with CPCB-approved biomedical waste disposal vendor.
  2. Sharps to be mutilated/disinfected and disposed in puncture-proof containers.
  3. Record pickup in Biohazard Waste Disposal Register (Annexure-1).

5.6 Emergency Spill Management

  1. Isolate the area and wear PPE.
  2. Cover spill with absorbent material soaked in 1% hypochlorite.
  3. Wait 30 minutes, collect waste, and autoclave before disposal.
  4. Record incident in Spill Incident Log (Annexure-2).

5.7 Documentation and Audit

  1. Maintain daily disposal logs and vendor handover receipts.
  2. QA to audit records monthly and verify log completeness.

6. Abbreviations

  • PPE: Personal Protective Equipment
  • CPCB: Central Pollution Control Board
  • QA: Quality Assurance

7. Documents

  1. Biohazard Waste Disposal Register (Annexure-1)
  2. Spill Incident Log (Annexure-2)
  3. Autoclave Record Log (Annexure-3)
See also  Biosimilars: SOP for Productivity Testing in Small-Scale Cultures - V 2.0

8. References

  • Biomedical Waste Management Rules, 2016 (India)
  • WHO Biosafety Manual, 4th Edition
  • GMP Guidelines – Cleaning & Waste Disposal

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Biohazard Waste Disposal Register

Date Type of Waste Qty (kg) Autoclaved Disposed By Vendor Receipt ID
03/05/2025 Contaminated Plastics 5.2 Yes Ajay Verma BMW-1023

Annexure-2: Spill Incident Log

Date Area Material Spilled Action Taken Reported By
01/05/2025 CLD-1 Spent Media Neutralized with bleach, autoclaved Sunita Reddy

Annexure-3: Autoclave Record Log

Date Batch ID Temp (°C) Time (min) Operator
03/05/2025 AUTO-0345 121 30 Vinay Pawar

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added emergency spill handling and audit trail requirements Regulatory alignment
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: API Manufacturing: SOP for Testing of Reaction Completion by TLC – V 2.0
Next Post: SOP for Post-Market Surveillance of Medical Devices

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version